News
Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.
